Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Loeppenthin, Katrine ; Dalton, Susanne Oksbjerg ; Johansen, Christoffer ; Andersen, Elisabeth ; Christensen, Mikkel Bring ; Pappot, Helle ; Petersen, Lone Nørgaard ; Thisted, Lise Bjerrum ; Frølich, Anne ; Mortensen, Christiane Ehlers ; Lassen, Ulrik ; Ørsted, Jytte ; Bidstrup, Pernille Envold. / Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication. In: British Journal of Cancer. 2020 ; Vol. 123, No. 6. pp. 1033-1040.

Bibtex

@article{4935e215d18e419285771692880af031,
title = "Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication",
abstract = "BACKGROUND: Multimorbidity is a growing challenge worldwide. In this nationwide study, we investigated the prevalence of multimorbidity and polypharmacy at the time of diagnosis across 20 cancers.METHODS: We conducted a nationwide register-based cohort study of all Danish residents with a first primary cancer diagnosed between 1 January 2005 and 31 December 2015. Multimorbidity was defined as one or more of 20 conditions (131 specific diagnoses) registered in the Danish National Patient Registry < 5 years before the cancer diagnosis. Polypharmacy was defined as five or more medications registered in the Danish National Prescription Registry and redeemed twice 2-12 months before the cancer diagnosis.RESULTS: We included 261,745 patients with a first primary cancer, of whom 55{\%} had at least one comorbid condition at diagnosis and 27{\%} had two or more. The most prevalent conditions at the time of cancer diagnosis were cardiovascular disease, chronic obstructive pulmonary disease, diabetes, stroke and depression/anxiety disorder. Polypharmacy was present in one-third of the cancer patients with antihypertensives, anti-thrombotic agents, anti-hyperlipidaemic agents, analgesics and diuretics as the most prevalent redeemed medications.CONCLUSION: Among patients with a newly established cancer diagnosis, 55{\%} had at least one comorbid condition and 32{\%} were exposed to polypharmacy.",
author = "Katrine Loeppenthin and Dalton, {Susanne Oksbjerg} and Christoffer Johansen and Elisabeth Andersen and Christensen, {Mikkel Bring} and Helle Pappot and Petersen, {Lone N{\o}rgaard} and Thisted, {Lise Bjerrum} and Anne Fr{\o}lich and Mortensen, {Christiane Ehlers} and Ulrik Lassen and Jytte {\O}rsted and Bidstrup, {Pernille Envold}",
year = "2020",
month = "9",
doi = "10.1038/s41416-020-0950-3",
language = "English",
volume = "123",
pages = "1033--1040",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

RIS

TY - JOUR

T1 - Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

AU - Loeppenthin, Katrine

AU - Dalton, Susanne Oksbjerg

AU - Johansen, Christoffer

AU - Andersen, Elisabeth

AU - Christensen, Mikkel Bring

AU - Pappot, Helle

AU - Petersen, Lone Nørgaard

AU - Thisted, Lise Bjerrum

AU - Frølich, Anne

AU - Mortensen, Christiane Ehlers

AU - Lassen, Ulrik

AU - Ørsted, Jytte

AU - Bidstrup, Pernille Envold

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: Multimorbidity is a growing challenge worldwide. In this nationwide study, we investigated the prevalence of multimorbidity and polypharmacy at the time of diagnosis across 20 cancers.METHODS: We conducted a nationwide register-based cohort study of all Danish residents with a first primary cancer diagnosed between 1 January 2005 and 31 December 2015. Multimorbidity was defined as one or more of 20 conditions (131 specific diagnoses) registered in the Danish National Patient Registry < 5 years before the cancer diagnosis. Polypharmacy was defined as five or more medications registered in the Danish National Prescription Registry and redeemed twice 2-12 months before the cancer diagnosis.RESULTS: We included 261,745 patients with a first primary cancer, of whom 55% had at least one comorbid condition at diagnosis and 27% had two or more. The most prevalent conditions at the time of cancer diagnosis were cardiovascular disease, chronic obstructive pulmonary disease, diabetes, stroke and depression/anxiety disorder. Polypharmacy was present in one-third of the cancer patients with antihypertensives, anti-thrombotic agents, anti-hyperlipidaemic agents, analgesics and diuretics as the most prevalent redeemed medications.CONCLUSION: Among patients with a newly established cancer diagnosis, 55% had at least one comorbid condition and 32% were exposed to polypharmacy.

AB - BACKGROUND: Multimorbidity is a growing challenge worldwide. In this nationwide study, we investigated the prevalence of multimorbidity and polypharmacy at the time of diagnosis across 20 cancers.METHODS: We conducted a nationwide register-based cohort study of all Danish residents with a first primary cancer diagnosed between 1 January 2005 and 31 December 2015. Multimorbidity was defined as one or more of 20 conditions (131 specific diagnoses) registered in the Danish National Patient Registry < 5 years before the cancer diagnosis. Polypharmacy was defined as five or more medications registered in the Danish National Prescription Registry and redeemed twice 2-12 months before the cancer diagnosis.RESULTS: We included 261,745 patients with a first primary cancer, of whom 55% had at least one comorbid condition at diagnosis and 27% had two or more. The most prevalent conditions at the time of cancer diagnosis were cardiovascular disease, chronic obstructive pulmonary disease, diabetes, stroke and depression/anxiety disorder. Polypharmacy was present in one-third of the cancer patients with antihypertensives, anti-thrombotic agents, anti-hyperlipidaemic agents, analgesics and diuretics as the most prevalent redeemed medications.CONCLUSION: Among patients with a newly established cancer diagnosis, 55% had at least one comorbid condition and 32% were exposed to polypharmacy.

U2 - 10.1038/s41416-020-0950-3

DO - 10.1038/s41416-020-0950-3

M3 - Journal article

VL - 123

SP - 1033

EP - 1040

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -

ID: 60921074